EP. 1: Pfizer's Citizen Petition on Biosimilar Communications
EP. 2: Combating Misinformation and Misconceptions About Biosimilars
EP. 3: Targeted Education for Biosimilar Stakeholders
EP. 4: US Versus EU Education on Biosimilars
EP. 5: The FDA's Approach to Biosimilar Education
EP. 6: Biosimilarity, Manufacturing Changes, and Comparability
EP. 7: Clinicians' Understanding of Manufacturing Changes
EP. 8: The Extrapolation of Indications
EP. 9: Selecting the Most Sensitive Population for Confirmatory Trials
EP. 10: Immunogenicity and Biosimilars
EP. 11: Misconceptions About Interchangeability
EP. 12: Clinical Studies for Biosimilars
EP. 13: The Future of US Biosimilars
EP. 14: The Role of Biosimilars in the US Healthcare System
EP. 15: Allowing the US Biosimilars Market to Flourish
EP. 16: Madelaine Feldman, MD: Prescribers' Understanding of Biosimilars
EP. 17: Molly Billstein Leber, PharmD, BCPS, FASHP: Dispelling Misconceptions About Biosimilar Approval and Use
EP. 18: Madelaine Feldman, MD: Physicians' Concerns Regarding Biosimilars
EP. 19: Molly Billstein Leber, PharmD, BCPS, FASHP: Pharmacists' Awareness of Biosimilars
EP. 20: Madelaine Feldman, MD: Practical Considerations for Biosimilars
EP. 21: Molly Billstein Leber, PharmD, BCPS, FASHP: Adoption of and Education on Biosimilars
EP. 22: Molly Billstein Leber, PharmD, BCPS, FASHP: Interchangeability Laws, Substitution, and the Future Role of Biosimilars
